Skip to content

Mannkind MNKD Total Equity

Total Equity at other companies

Eli Lilly logo
Eli LillyLLY
$31.2B+97.9%
LQD
Liquidia CorporationLQDA
$108.58M+118%
Tenet Healthcare logo
Tenet HealthcareTHC
$4.81B+15.1%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$202.86M+64.9%
Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$638.14M+86.8%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$132.4M-14.7%

Other financials

Income statement

See full
Revenue$90.2M+15.1%
Gross profit$82.7M+10.8%
Operating income-$1.7M-107%
Net income-$16.6M-226%
EPS (diluted)-$0.05-225%

Balance sheet

See full
Cash & equivalents$52.8M+11.7%
Total debt$12.2M-9.4%
Total assets$744.4M+81.5%

Cash flow

See full
Operating cash flow-$5.4M+15.9%
CapEx$1.9M+470%
Free cash flow-$7.2M-8.0%

Valuation

See full
Market cap$1.19B+3.5%
Enterprise value$1.15B+3.0%
P/E228.5×
P/S3.3×-0.6×

Profitability

See full
Gross margin91.5%-2.6pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity-8.8%
Debt / equity-0.2×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Mannkind’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mannkind's total equity?
Mannkind (MNKD) reported total equity of -$59.2M in Q1 2026.
How has Mannkind's total equity changed year-over-year?
Mannkind's total equity decreased by 1.0% year-over-year, from -$58.62M to -$59.2M.
What is the long-term trend for Mannkind's total equity?
Over 5 years (2020 to 2025), Mannkind's total equity has grown at a -22.3% compound annual growth rate (CAGR), from -$180.42M to -$51.02M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.